StockMarketWire.com - Pharmaceutical company AstraZeneca said its drug to treat extensive-stage small cell lung cancer had been approved in China.

The approval was based on a phase 3 study showing imfinzi plus chemotherapy demonstrated a 'statistically significant and clinically meaningful improvement in overall survival versus chemotherapy alone,' the company said.




Story provided by StockMarketWire.com